


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**In the Claims:**

1. (Currently amended)      A pharmaceutical composition for dry powder inhalation in the respiratory tract of a human, comprising a compound according to Formula (I) hereinbelow:



(I)

wherein:

R<sub>2</sub> and R<sub>3</sub> are, independently, selected from the group consisting of straight or branched chain lower alkyl groups (having preferably from 1 to 6 carbon atoms), cycloalkyl groups (having from 5 to 6 carbon atoms), cycloalkyl-alkyl (having 6 to 10 carbon atoms), 2-thienyl, 2-pyridyl, phenyl, phenyl substituted with an alkyl group having not in excess of 4 carbon atoms, and phenyl substituted with an alkoxy group having not in excess of 4 carbon atoms; and

X<sup>-</sup> represents an anion associated with the positive charge of the N atom; such that the compound is in quaternary salt form; and a pharmaceutically acceptable carrier or diluent suitable for dry powder oral inhalation in a human.

2. (previously presented)      A pharmaceutical composition according to claim 1 wherein the orientation of the alkyl chain attached to the tropane ring is endo.

3. (Currently amended) A pharmaceutical composition ~~compound~~ according to claim 2 selected from the group consisting of:

(3-*endo*)-3-(2,2-di-2-thienylethenyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide;

(3-*endo*)-3-(2,2-diphenylethenyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide;

(3-*endo*)-3-(2,2-diphenylethenyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane 4-methylbenzenesulfonate;

(3-*endo*)-8,8-dimethyl-3-[2-phenyl-2-(2-thienyl)ethenyl]-8-azoniabicyclo[3.2.1]octane bromide; and

(3-*endo*)-8,8-dimethyl-3-[2-phenyl-2-(2-pyridinyl)ethenyl]-8-azoniabicyclo[3.2.1]octane bromide.

4. (Currently amended) A pharmaceutical composition according to claim 1 [[3]] wherein X<sup>-</sup> is selected from the group consisting of chloride, bromide, iodide, sulfate, benzene sulfonate and toluene sulfonate.

5. (Cancelled)

6. (Currently amended) A method of inhibiting the binding of acetylcholine to ~~acetylcholine to its receptors in a mammal~~ an acetylcholine receptor in a human in need thereof, comprising administering a safe and effective amount of a compound which comprises contacting the acetylcholine receptor with an effective amount of a composition according to claim 1, and wherein the method of contacting the receptor with the composition is via inhalation by the mouth of the human.

7. (currently amended) A method of ~~treating a~~ inhibiting the binding of acetylcholine to a M<sub>3</sub> muscarinic acetylcholine receptor in the respiratory tract of a human in need thereof, which comprises contacting the M<sub>3</sub> muscarinic acetylcholine receptor with an effective amount of a composition mediated disease, wherein acetylcholine binds to said receptor, comprising administering a safe and effective amount of a compound according to claim 1 and wherein the method of contacting the receptor with the composition is via inhalation by the mouth of the human.

8. (Currently amended) A method according to claim 7 wherein the binding of the M3 muscarinic acetylcholine receptor ~~disease is selected from the group consisting of~~ is useful in the treatment of chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema or allergic rhinitis.

9. (currently amended) A method according to claim 7 wherein administration is via inhalation via the mouth ~~or nose~~ from a medicament dispenser which is a reservoir dry powder inhaler.

10. (previously presented) A method according to claim 7 wherein administration is via a medicament dispenser selected from a reservoir dry powder inhaler, a multi-dose dry powder inhaler or a metered dose inhaler.

11. (currently amended) A method according to claim 7 wherein the composition has a duration of action of 12 hours or more ~~for a 1 mg dose.~~

12. (previously presented) A method according to claim 11 wherein the composition has a duration of action of 24 hours or more.

13. (previously presented) A method according to claim 12 wherein the composition has a duration of action of 36 hours or more.

14. (new) A method of treating chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema or allergic rhinitis in a human in need thereof, comprising administering to said human by inhalation via the mouth, an effective amount of a composition according to Claim 1.

15. (new) The method according to Claim 14 wherein the treatment is for chronic obstructive lung disease or asthma.

16. (new) A method of administering to a human in need thereof a pharmaceutical composition according to claim 1, wherein administration is via inhalation via the mouth.

17. (new) The method according to Claim 16 wherein the administration of the pharmaceutical composition is via inhalation via the mouth from a medicament dispenser which is a reservoir dry powder inhaler.

18. (new) The method according to Claim 16 wherein the administration of the pharmaceutical composition is via inhalation via the mouth from a medicament dispenser which is a metered dose inhaler.

19. (new) The method according to Claim 16 wherein the administration of the pharmaceutical composition is via inhalation via the mouth from a medicament dispenser which is a multi-dose dry powder inhaler.

20. (new) The composition according to Claim 1 wherein the pharmaceutically acceptable carrier or diluent suitable for dry powder oral inhalation is selected from lactose or starch.